De novo protein structure prediction

Monod Bio Announces Publication in Nature Highlighting De Novo Protein Technology Platform for the Creation of Novel Luciferases

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Technology, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Software, Genetics, Science, Clinical Trials, Monod, Protein, Paper, University, De novo protein structure prediction, De novo, University of Washington Department of Bioengineering, Algorithm, Howard Hughes Medical Institute, UW, Enzyme, University of Washington School of Medicine, Bio, Machine learning, Luciferin, Biochemistry, IPD, Luciferase, Rare-earth element, Fine chemical, Medicine, Nature

As reported in the journal Nature, a team based at the Institute for Protein Design (IPD) at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases.

Key Points: 
  • As reported in the journal Nature, a team based at the Institute for Protein Design (IPD) at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases.
  • Combining these biosensors with the de novo luciferases will create new commercial opportunities for Monod Bio.
  • “LuxSit and its underlying de novo protein design technology are fundamental to what we are developing at Monod Bio.
  • “We continue using LuxSit, machine learning, and de novo protein design to advance our unique biosensor pipeline aimed to improve human health.

Protein Sequencing Market Size, Share & Trends Analysis Report 2022 - Global Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Biotechnology, Health, Other Health, Organization, Patent, Proteome, Bristol Myers Squibb, Therapy, Yale University, Rheumatoid arthritis, Mass spectrometry, De novo protein structure prediction, Vaccination, Intellectual property, Product-service system, University, Biomedical Research, Research, USD, Application, WHO, Proteomics, Amgen, SWOT analysis, Growth, Serum, Genomics, COVID-19, Cancer, Fine chemical, Pharmaceutical industry

The "Protein Sequencing Market Size, Share & Trends Analysis Report by Product & Service (Protein Sequencing Products, Protein Sequencing Services), by Application, by End-user, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Sequencing Market Size, Share & Trends Analysis Report by Product & Service (Protein Sequencing Products, Protein Sequencing Services), by Application, by End-user, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • For instance, in May 2022, Amphista Therapeutics announced a collaboration with Bristol Myers Squibb for discovering and developing small-molecule protein degraders.
  • Hence, the rising demand for protein degradation is anticipated to extend the application scope for protein sequencing.
  • A study published in September 2022 performed 97,437 COVID-19 protein sequencing to detect non-synonymous mutations in 26 various sequences.

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Protein, De novo, Research, Inflammation, Cancer, Half-life, Autoimmunity, ASH, MD, Lupus, Society, Therapy, De novo protein structure prediction, Publication, Patient, Fine chemical, Vaccine

The data are being disclosed today as an oral presentation at the American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • The data are being disclosed today as an oral presentation at the American Society of Hematology (ASH) Annual Meeting.
  • The presentation highlights two important features of Neoleukin’s de novo protein technology: 1) the ability to target de novo cytokine mimetics to specific cell types, i.e.
  • T-regulatory cells; and 2) precision-tuned de novo payloads that have minimal effects on non-targeted cells.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.   For more information, please visit the Neoleukin website: www.neoleukin.com.

Ordaōs Announces Appointment of Ziwei Liang, PhD to Role of Chief Science Officer

Retrieved on: 
Thursday, December 15, 2022
Department of Mechanical Engineering, Imperial College London, Therapy, Probability, Organic acid, De novo protein structure prediction, Design engineer, IND, Imperial College London, Doctor of Philosophy, Protein, Bachelor of Science, GlaxoSmithKline, Solubility, Medicine, AI, Toussaint Louverture International Airport, Multimedia, Health, Machine learning, Pharmaceutical industry, Management, Vaccine, Fine chemical, Biotechnology, Ordas

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Ordas, a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, today announced that company co-founder Ziwei Liang, PhD, has been elevated to the role of Chief Science Officer for this emerging biotech company.

Key Points: 
  • NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Ordas, a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, today announced that company co-founder Ziwei Liang, PhD, has been elevated to the role of Chief Science Officer for this emerging biotech company.
  • "As our company enters a time of rapid evolution, having Ziwei's leadership, inventiveness and contagious enthusiasm will be critical to our progress.
  • Dr. Liang has a strong scientific background and expertise in translational research and medicine and the application of bioinformatics analyses.
  • "I am thrilled to take on this position to further Ordas' mission and scientific leadership role in creating novel mini-proteins," said Dr. Liang.

AI Proteins Secures $18.2 Million Seed Round to Pioneer High-Throughput Platform for Advanced Miniprotein Therapeutics

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Protein, Research, Therapy, Institute, Industry, Biology, IPI, DRS, Artificial intelligence, Interim, Hospital, Peptide, Social media, De novo, CSO, Harvard Medical School, Health, Technology, De novo protein structure prediction, Dennison, Fine chemical, Vaccine, Milk

Whereas traditional approaches are limited to editing existing natural proteins, de novo design enables engineers to build the proteins they wantrather than modifying the proteins they have.

Key Points: 
  • Whereas traditional approaches are limited to editing existing natural proteins, de novo design enables engineers to build the proteins they wantrather than modifying the proteins they have.
  • AI Proteins is re-imagining protein therapeutics with a novel approach for designing entirely new proteins.
  • Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications.
  • The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that can be optimized for oral delivery.

Dental Care Alliance Names Chief Development and Growth Officers

Retrieved on: 
Friday, September 2, 2022
Partnership, Dentistry, Business development, Anhui University of Finance and Economics, Senior, De novo protein structure prediction, DCA, ADP, Goal, GlaxoSmithKline, Economics, Leadership, DSO, Christy, Dental care, University of Oxford, Chief Dental Officer (Canada), Stetson University, Growth, Industry, Dentist, Patient, Management

SARASOTA, Fla., Sept. 1, 2022 /PRNewswire-PRWeb/ -- Dental Care Alliance (DCA) proudly announces that Christine Heald has joined the DCA leadership team as Chief Development Officer. David Pegg, an Ally Since 2017, will take on a new role spearheading efforts to elevate DCA's overall growth strategy and direction as Chief Growth Officer for the organization.

Key Points: 
  • Dental Care Alliance (DCA) proudly announces that Christine Heald has joined the DCA leadership team as Chief Development Officer.
  • SARASOTA, Fla., Sept. 1, 2022 /PRNewswire-PRWeb/ --Dental Care Alliance (DCA) proudly announces that Christine Heald has joined the DCA leadership team as Chief Development Officer.
  • David Pegg, an Ally Since 2017, will take on a new role spearheading efforts to elevate DCA's overall growth strategy and direction as Chief Growth Officer for the organization.
  • For the last five years, David Pegg has led the team responsible for the tremendous growth and strategic business development for Dental Care Alliance; and he will now take those efforts to the next level as DCA's Chief Growth Officer.

Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Retrieved on: 
Monday, August 15, 2022
Other Health, Nanotechnology, Other Science, Pharmaceutical, Research, Oncology, Software, Medical Devices, Infectious Diseases, Genetics, Data Management, Science, Technology, Clinical Trials, Cardiology, FDA, Biotechnology, Health, COVID-19, Machine learning, Partner (business rank), Antibody, Biomarker, Synthetic biology, CEO, Monod, De novo protein structure prediction, Technology, Protein engineering, De novo, Research, Life, Founder, Institute, Patient, Engineering, COVID-19, Partnership, Howard Hughes Medical Institute, Biotechnology, Architecture, Virus, Nature Biotechnology, Biology, University of Washington School of Medicine, Protein, Software, University, IPD, Medicine, Biochemistry, Bio, Fine chemical, Management, Nature

Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.

Key Points: 
  • Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.
  • Monod was founded in November 2021 from technology developed at David Bakers lab at the University of Washington Institute for Protein Design.
  • Our partnership with Monod Bio reflects our commitment to back extraordinary teams unlocking breakthrough innovation at the intersection of technology and life sciences.
  • Monod Bio's innovative biosensor platform technology uses computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and cost-effective analytical assays.

Bioretec has submitted a market authorization request for its bioresorbable RemeOs™ magnesium screw in the U.S.

Retrieved on: 
Thursday, May 5, 2022
Bone, Health care, Food, Safety, De novo protein structure prediction, Patient, Trauma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, De novo, CEO, Technology, Growth, Medical device, Dentistry, EU

HELSINKI, May 5, 2022 /PRNewswire/ -- 

Key Points: 
  • Bioretec Ltd Company Announcement 5 May 2022 at 9.00 a.m. EEST
    Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted a De Novo request for market authorization in the United States for the RemeOs trauma screw based on bioresorbable magnesium alloy.
  • Bioretec estimates the market authorization in the United States to be granted during the second half of 2022.
  • The De Novo request provides a registration pathway for novel medical devices for which there is no predicate device available in the U.S. market.
  • The submission of the De Novo market authorization application has been preceded by interactive discussions under the FDA's Breakthrough Device program.

Bioretec has submitted a market authorization request for its bioresorbable RemeOs™ magnesium screw in the U.S.

Retrieved on: 
Thursday, May 5, 2022
Bone, Health care, Food, Safety, De novo protein structure prediction, Patient, Trauma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, De novo, CEO, Technology, Growth, Medical device, Dentistry, EU

HELSINKI, May 5, 2022 /PRNewswire/ -- 

Key Points: 
  • Bioretec Ltd Company Announcement 5 May 2022 at 9.00 a.m. EEST
    Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted a De Novo request for market authorization in the United States for the RemeOs trauma screw based on bioresorbable magnesium alloy.
  • Bioretec estimates the market authorization in the United States to be granted during the second half of 2022.
  • The De Novo request provides a registration pathway for novel medical devices for which there is no predicate device available in the U.S. market.
  • The submission of the De Novo market authorization application has been preceded by interactive discussions under the FDA's Breakthrough Device program.

Three New Banks Select Jack Henry's Technology to Serve Local Communities

Retrieved on: 
Thursday, March 17, 2022
SEC, Solution, Technology, Jack Henry & Associates, U.S. Securities and Exchange Commission, News, Partnership, Multimedia, Software as a service, Digital technology, Bank, NASDAQ, JKHY, Company, CEO, De novo protein structure prediction, Growth, Industry, Efficiency, Ecosystem, Cryptocurrency, Legume, Online shopping

MONETT, Mo., March 17, 2022 /PRNewswire/ -- Jack Henry & Associates, Inc.® (NASDAQ: JKHY) announced today that Bank of Burlington, RockPoint Bank and Moultrie Bank & Trust each have selected Jack Henry's technology platform to help them expand access to financial services in their local communities.

Key Points: 
  • Tenn.-based RockPoint Bank, Ga.-based Moultrie Bank & Trust, and Vt.-based Bank of Burlington were recently formed to serve local communities that had limited access to local financial services due to industry consolidation.
  • The banks needed a digitally focused, open, and flexible technology provider to support rapid growth and help them compete with large banks as well as non-traditional financial institutions.
  • With Jack Henry, the banks gain a strategic and comprehensive technology plan with competitive core solutions and future-ready services such as Banno Digital PlatformTM and LoanVantage .
  • It is an opportunity to build a technology strategy with easy access to a broad ecosystem of Jack Henry solutions and third-party fintechs of choice.